What is the AbbVie stock forecast for 2025?

The Abbvie stock forecast for 2025 had the price at $259.018. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. When looking for ABBV stock forecasts, it’s important to bear in mind that analysts’ forecasts can be wrong.

How far is AbbVie stock from the 52-week high?

According to the current price, AbbVie is 89.39% away from the 52-week high. What are analysts forecasts for AbbVie stock? The 47 analysts offering price forecasts for AbbVie have a median target of 162.40, with a high estimate of 200.00 and a low estimate of 113.00. The median estimate represents a 92.52 difference from the last price of 150.25.

Will AbbVie's top line decline in 2022?

Considering that Humira alone made up about 37% of AbbVie's total revenue in 2022, it's not surprising that management expects its top line to decline for the next couple of years. Investors just got a taste of this dire situation when AbbVie released its first-quarter results.

What is AbbVie's forecast for Skyrizi and Rinvoq?

AbbVie is predicting peak sales near $4 billion for this drug. AbbVie has issued sales guidance for Skyrizi and Rinvoq, which calls for more than $15 billion in combined sales by 2025. The company has recently reaffirmed this guidance, so there may not be an update.